Form 4: Mirum Pharmaceuticals Director Sells All Direct Stock Holdings in Pre-Planned Transactions

A director at Mirum Pharmaceuticals, Saira Ramasastry, has reported the sale of all her directly held common stock and shares acquired through option exercise, resulting in zero direct beneficial ownership.

Summary

• Saira Ramasastry, a Director of Mirum Pharmaceuticals, Inc. (MIRM), reported multiple transactions involving the company's common stock.
• On June 2, 2025, Ms. Ramasastry disposed of 5,703 shares of common stock at a price of $46.2023 per share, leaving her with 0 shares beneficially owned after this transaction.
• On June 3, 2025, Ms. Ramasastry exercised stock options to acquire 2,500 shares of common stock at an exercise price of $14.12 per share.
• Immediately following the option exercise on June 3, 2025, she disposed of these 2,500 shares of common stock at a price of $45.7407 per share, again resulting in 0 shares beneficially owned from this specific set of transactions.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), indicating they were pre-planned.
• After all reported transactions, Saira Ramasastry holds 0 shares of Mirum Pharmaceuticals, Inc. common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling all direct holdings, despite the transactions being pre-planned under a Rule 10b5-1 plan. The complete divestment of direct equity by an insider can raise concerns about their long-term alignment and confidence.

Positives

• The exercise of stock options indicates that the company's stock price was significantly above the option exercise price ($14.12), suggesting a favorable market valuation for the options.
• The transactions were conducted under a Rule 10b5-1 plan, which indicates pre-planning and can mitigate concerns about opportunistic insider selling.

Negatives

• A director, Saira Ramasastry, has sold all of her directly held common stock, including shares acquired through option exercise, resulting in zero direct beneficial ownership of Mirum Pharmaceuticals, Inc. shares.
• Significant insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it may suggest a lack of long-term confidence from an insider.

Risks

• Investor sentiment may be negatively impacted by the perception of a director divesting all direct stock holdings, potentially leading to short-term stock price volatility.
• The complete divestment of direct shares by a director could raise questions about their long-term alignment with shareholder interests, despite the transactions being pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is an individual insider transaction report and does not directly relate to broader industry trends or competitor performance, other than reflecting the individual's personal financial planning and equity management within the pharmaceutical sector.

Stakeholder Impact

• Shareholders may react to the news of a director selling all direct stock holdings, potentially leading to a negative impact on investor confidence and short-term stock price movements.
• Employees are not directly impacted by this specific insider transaction report.

Key Dates

Keywords

SEC Form 4, Insider Trading, Stock Sale, Option Exercise, Mirum Pharmaceuticals, MIRM, Saira Ramasastry, Rule 10b5-1, Beneficial Ownership